| 奥布替尼治疗B细胞淋巴瘤中国专家推荐临床应用指导原则（2021年版） |
| |
| 引用本文： | 中国临床肿瘤学会.奥布替尼治疗B细胞淋巴瘤中国专家推荐临床应用指导原则（2021年版）[J].白血病．淋巴瘤,2021,30(8):455-460. |
| |
| 作者姓名： | 中国临床肿瘤学会 |
| |
| 摘 要： | Bruton酪氨酸激酶（BTK）抑制剂作为小分子靶向药物，目前已经被批准用于慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、套细胞淋巴瘤和华氏巨球蛋白血症等的治疗。奥布替尼是首创新药，于2020年12月25日获批上市，其在临床实践中的应用数据尚待完善。为了进一步规范奥布替尼在B细胞淋巴瘤中的临床应用，专家组成员结合BTK抑制剂的应用现状及已经公布的奥布替尼相关研究数据，制定了该临床应用指导原则，供临床医生参考使用。
|
| 关 键 词： | 淋巴瘤，B细胞 Bruton酪氨酸激酶抑制剂 奥布替尼 治疗结果 实践指南 |
Guidance for the clinical practice of orelabrutinib in B-cell lymphoma recommended by Chinese experts (2021 version) |
| |
| Abstract: | As a small molecule agent, Bruton tyrosine kinase (BTK) inhibitor has been approved in treatment of chronic lymphocytic leukemia/small lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia. Orelabrutinib as a novel BTK inhibitor was launched on December 25, 2020, however, the data of clinical practice remains limited. In order to standardize the clinical practice of orelabrutinib in B-cell lymphoma treatment, the Chinese experts work out this clinical guidance by combining the current clinical application of BTK inhibitors and published data of orelabrutinib to provide references for clinical physicians. |
| |
| Keywords: | Lymphoma B-cell Bruton's tyrosine kinase inhibitors Orelabrutinib Treatment outcome Practice guideline |
| 本文献已被 万方数据 等数据库收录！ |
